Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CG001419 Tablets in Adult Patients With Locally Advanced/Metastatic Solid Tumors Harboring NTRK Gene Fusions, Mutations, or Amplification/Over Expression.

NCT07394374 is registered in ClinicalTrials.gov with Cullgen (Shanghai),Inc as lead sponsor.

NCT NCT07394374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07394374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CG001419 Tablets in Adult Patients With Locally Advanced/Metastatic Solid Tumors Harboring NTRK Gene Fusions, Mutations, or Amplification/Over Expression.
Lead sponsor
Cullgen (Shanghai),Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 20, 2023
Completion date
August 30, 2030
Enrollment
42 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ntrk, ntrk fusion positive, ntrk gene fusion, solid tumors harboring ntrk fusion